Tradercommunity Clickoptions Forum

[Newsagent]

PR inside: Cellectis S.A. (CLLS) Investigation: Bronstein, Gewirtz & Grossman, ...

(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 23, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cellectis S.A. ("Cellectis" or "the Company") (NASDAQ:CLLS). Investors who purchased Cellectis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/cellectis-sa-clls-class_action_lawsuit.

Cellectis Investigation Details

On September 14, 2026, Cellectis announced it would prioritize in vivo gene editing therapies (HEAL-101 and HEAL-201) over CAR-T cell therapies. The Company concurrently announced it plans to discontinue the development of CAR-T cell therapies lasme-cel and eti-cel. In the accompanying conference call, the Company's ..

https://reports.pr-inside.com/cellectis ... 226528.htm
Copyright PR-Inside.com 2026